Skip to content
Disclosery

AJU IB Investment Co., Ltd.

Follow

13F filer, CIK 1710065, Seoul, Korea Republic of

AJU IB Investment Co., Ltd. reported $22,787,545 across 7 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-10.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001140361-26-004468

Period
2025-12-31
Reported value
$22.8M
Holdings
7
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ACLXreduced-824,071-$53.7M
KYMRreduced-437,411-$34M
SUTRO BIOPHARMA INCreduced-157,500-$1.82M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001140361-26-004468, largest first. % of portfolio is the value over $22,787,545, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 1,047,557 shares; 2025Q1: 1,047,557 shares; 2025Q2: 1,047,557 shares; 2025Q3: 1,047,557 shares; 2025Q4: 223,486 shares 223,486$14.6M63.94%-824,071Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 754,678 shares; 2025Q1: 754,678 shares; 2025Q2: 754,678 shares; 2025Q3: 754,678 shares; 2025Q4: 754,678 shares 754,678$4.14M18.18%0
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 457,059 shares; 2025Q1: 457,059 shares; 2025Q2: 457,059 shares; 2025Q3: 457,059 shares; 2025Q4: 19,648 shares 19,648$1.53M6.71%-437,411Timeline
SEERSEER INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 816,375 shares; 2025Q1: 816,375 shares; 2025Q2: 816,375 shares; 2025Q3: 816,375 shares; 2025Q4: 816,375 shares 816,375$1.49M6.56%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 667,742 shares; 2025Q1: 667,742 shares; 2025Q2: 667,742 shares; 2025Q3: 667,742 shares; 2025Q4: 667,742 shares 667,742$427K1.88%0Timeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 99,503 shares; 2025Q1: 99,503 shares; 2025Q2: 12,437 shares; 2025Q3: 12,437 shares; 2025Q4: 12,437 shares 12,437$421K1.85%0
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 175,000 shares; 2025Q1: 175,000 shares; 2025Q2: 175,000 shares; 2025Q3: 175,000 shares; 2025Q4: 17,500 shares 17,500$202K0.89%-157,500

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001140361-26-004468 base2026-02-10acceptance time not in the bulk data set